Monte Rosa Therapeutics (GLUE) Stock Chart & Stock Price History $7.74 -0.74 (-8.73%) (As of 11/15/2024 ET) Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Monte Rosa Therapeutics Stock Price Performance 5 Day Performance-15.22%1 Month Performance+40.98%3 Month Performance+65.38%6 Month Performance+48.85%Year-To-Date Performance+36.99%1 Year Performance+131.04% Receive GLUE Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. GLUE Stock Chart for Sunday, November, 17, 2024 GLUE Chart by TradingView Monte Rosa Therapeutics Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization11/15/2024$8.48$7.74-8.73%$8.63$7.64876,524 shs$475.55 million11/14/2024$8.63$8.48-1.74%$8.92$8.38738,448 shs$521.01 million11/13/2024$9.13$8.63-5.48%$9.60$8.62669,410 shs$530.23 million11/12/2024$10.01$9.13-8.79%$10.22$9.011.38 million shs$560.34 million11/11/2024$9.26$10.01+8.10%$10.40$9.321.72 million shs$614.34 million11/08/2024$9.53$9.26-2.83%$9.84$9.03793,886 shs$568.31 million Get the Latest News and Ratings for GLUE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/07/2024$9.45$9.53+0.85%$9.85$9.321.13 million shs$584.86 million11/06/2024$9.36$9.45+0.96%$9.70$8.90928,758 shs$579.95 million11/05/2024$8.84$9.36+5.88%$9.37$8.46686,679 shs$574.42 million11/04/2024$8.90$8.84-0.67%$9.12$8.484.57 million shs$542.54 million11/01/2024$8.50$8.90+4.71%$8.94$8.31745,700 shs$546.19 million10/31/2024$9.22$8.50-7.81%$9.54$8.501.28 million shs$521.67 million10/30/2024$9.37$9.22-1.60%$9.68$8.911.85 million shs$465.72 million10/29/2024$9.48$9.37-1.16%$9.52$8.355.85 million shs$473.30 million10/28/2024$4.89$9.48+93.87%$12.40$6.1594.92 million shs$478.85 million10/25/2024$4.87$4.89+0.41%$5.11$4.8689,931 shs$247.00 million10/24/2024$4.87$4.87$5.04$4.8581,561 shs$245.99 million10/23/2024$5.31$4.87-8.29%$5.33$4.76166,880 shs$245.99 million10/22/2024$5.45$5.31-2.57%$5.40$5.17119,377 shs$268.22 million10/21/2024$5.52$5.45-1.27%$5.52$5.3187,345 shs$275.29 million10/18/2024$5.49$5.52+0.55%$5.53$5.29120,406 shs$278.83 million10/17/2024$5.50$5.49-0.18%$5.69$5.34122,780 shs$277.31 million10/16/2024$5.12$5.50+7.42%$5.60$5.10383,754 shs$277.82 million Related Companies CCCC Stock Price Chart MCRB Stock Price Chart IVVD Stock Price Chart BLUE Stock Price Chart KRON Stock Price Chart NAMS Stock Price Chart HRMY Stock Price Chart WVE Stock Price Chart SYRE Stock Price Chart RXRX Stock Price Chart Receive GLUE Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:GLUE) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
